Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPrime Therapeutics Isturisa Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentPrime TherapeuticsPolicy N/A

    Isturisa Prior Authorization with Quantity Limit Program Summary

    Customize your policy alerts

    Sign up for all prime_therapeutics policy alerts

    Know when prime_therapeutics releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs commercial coverage of Isturisa tablets for eligible patients, including initial authorization, renewal, and requests exceeding the program quantity limits. It applies to providers seeking coverage through the Boeing formulary administered by Prime Therapeutics.

    Policy Summary
    PayerPrime Therapeutics
    PolicyIsturisa Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit documentation supporting the diagnosis, applicable prior treatment history, specialist involvement or consultation, and absence of contraindications for initial authorization.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    12 monthsInitial authorization duration
    12 monthsRenewal authorization duration
    240 tablets1 mg quantity limit per 30 days
    360 tablets5 mg quantity limit per 30 days

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Cushing syndromePrimary clinical indication described

    Coverage Criteria

    Initial therapy

    Initial Evaluation Target Agent(s) will be approved when ALL of the following are met.

    Initial authorization

    • Eligible indication

      • Cushing syndrome pathway

        • Surgical status

          • The patient had an inadequate response to surgery.
          • The patient is not a candidate for surgery.
        • Conventional-agent requirement

          • The patient tried and had an inadequate response to at least one of the following conventional agents: mifepristone, Signifor/Signifor LAR (pasireotide), Recorlev (levoketoconazole), cabergoline, metyrapone, or Lysodren (mitotane).
          • The patient has an intolerance or hypersensitivity to mifepristone, pasireotide, or levoketoconazole.
          • The patient has an FDA-labeled contraindication to mifepristone, pasireotide, and levoketoconazole.
        • Ketoconazole requirement

          • The patient tried ketoconazole tablets and had an inadequate response.
          • The patient has an intolerance or hypersensitivity to ketoconazole tablets.

            Medical records are required.

          • The patient has an FDA-labeled contraindication to ketoconazole tablets.

            Medical records are required.

      • Other FDA-labeled indication pathway

        • Age requirement

          • The patient's age is within FDA labeling for the requested indication for the requested agent.
          • There is support for using the requested agent for the patient's age for the requested indication.
    • General requirements

      • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or the prescriber has consulted with a specialist in that area.
      • The patient will not be using the requested agent in combination with glucocorticoid replacement therapy for the requested indication.
      • The patient does not have any FDA-labeled contraindications to the requested agent.

    Continuation therapy

    Target Agent(s) will be approved when ALL of the following are met.

    Renewal authorization

    • The patient has been previously approved for the requested agent through the plan's prior authorization process.

      Patients not previously approved through the plan require initial evaluation review.

    • The patient has had clinical benefit with the requested agent.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or the prescriber has consulted with a specialist in that area.
    • The patient will not be using the requested agent in combination with glucocorticoid replacement therapy for the requested indication.
    • The patient does not have any FDA-labeled contraindications to the requested agent.

    Quantity-limit criteria

    Quantity Limit for the Target Agent(s) will be approved when ONE of the following is met.

    Quantity-limit approval

    • The requested quantity does not exceed the program quantity limit.
    • Higher-dose exception

      • The requested agent does not have a maximum FDA-labeled dose for the requested indication.
      • There is support for therapy with a higher dose for the requested indication.
    • Higher-strength exception

      • The requested quantity does not exceed the maximum FDA-labeled dose for the requested indication.

    Use with glucocorticoid replacement therapy for the requested indication is excluded from approval.

    Patients with an FDA-labeled contraindication to the requested agent are excluded from approval.

    Authorization and Documentation Requirements

    Prior Authorization

    Initial Authorization Eligibility

    Request initial authorization when the patient has Cushing syndrome meeting the required clinical pathway or has another FDA-labeled indication for Isturisa and the requested route of administration. For an FDA-labeled indication, the patient must be within the labeled age range or there must be support for use at the patient's age.

    • Cushing syndrome pathway: inadequate response to surgery or the patient is not a candidate for surgery.
    • The prescriber must be a specialist in the area of the diagnosis, such as an endocrinologist, or must have consulted with an appropriate specialist.
    Prior Authorization

    Renewal Authorization Required

    For renewal authorization, confirm that the patient was previously approved for Isturisa through the plan's prior authorization process and has experienced clinical benefit. Specialist prescribing or consultation, absence of prohibited glucocorticoid replacement therapy, and absence of FDA-labeled contraindications are also required.

    • Patients without prior plan approval require initial evaluation review.

    Policy Background

    Isturisa (osilodrostat) is reviewed for treatment of Cushing syndrome or another FDA-labeled indication for the requested agent and route of administration. For Cushing syndrome, initial coverage requires an inadequate response to surgery or that the patient is not a surgical candidate, along with specified prior-treatment requirements involving conventional agents and ketoconazole tablets. Continued coverage requires documented clinical benefit and ongoing compliance with specialist involvement, combination-therapy, and contraindication requirements.

    Isturisa Initial Therapy

    Isturisa initial therapy

    Initial Evaluation Target Agent(s) will be approved when ALL of the following are met.

    Initial Isturisa authorization

    • Eligible indication

      • Cushing syndrome pathway

        • Surgical status

          • The patient had an inadequate response to surgery.
          • The patient is not a candidate for surgery.
        • Conventional-agent requirement

    Isturisa Continuation Therapy

    Isturisa continuation therapy

    Target Agent(s) will be approved when ALL of the following are met.

    Isturisa renewal authorization

    • The patient has been previously approved for Isturisa through the plan's prior authorization process.

      Patients not previously approved through the plan require initial evaluation review.

    • The patient has had clinical benefit with Isturisa.
    • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or the prescriber has consulted with a specialist in that area.
    • The patient will not be using Isturisa in combination with glucocorticoid replacement therapy for the requested indication.

    Required Prior Therapy

    StepRequired prior therapyException pathwaysDocumentation
    1Try at least one conventional agent: mifepristone; Signifor/Signifor LAR (pasireotide); Recorlev (levoketoconazole); cabergoline; metyrapone; or Lysodren (mitotane), with an inadequate response.Instead of an inadequate response, intolerance or hypersensitivity to mifepristone, pasireotide, or levoketoconazole; or an FDA-labeled contraindication to all three, may satisfy this requirement. The patient must also try ketoconazole tablets and have an inadequate response, unless there is intolerance, hypersensitivity, or an FDA-labeled contraindication to ketoconazole tablets.Medical records are required when relying on ketoconazole intolerance, hypersensitivity, or contraindication.

    Program Quantity Limits

    Quantity limit
    MedicationOsilodrostat phosphate tablets 1 mg
    Quantity limit240 tablets per 30 days
    Quantity limit
    MedicationOsilodrostat phosphate tablets 5 mg
    Quantity limit360 tablets per 30 days
    Policy Summary
    PayerPrime Therapeutics
    PolicyIsturisa Prior Authorization with Quantity Limit Program Summary
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateNov 15, 2026
    Next Review DateN/A
    Key ActionSubmit documentation supporting the diagnosis, applicable prior treatment history, specialist involvement or consultation, and absence of contraindications for initial authorization.
    SourceLink
    On This Page
    Coverage CriteriaAuthorization and Documentation RequirementsPolicy BackgroundIsturisa Initial TherapyIsturisa Continuation TherapyRequired Prior TherapyProgram Quantity Limits
    There is support for why the requested quantity cannot be achieved with a lower quantity of a higher-strength tablet that does not exceed the program quantity limit.
    Step Therapy

    Required Prerequisite Therapy

    For Cushing syndrome, document that the patient had an inadequate response to conventional therapy or meets an applicable exception before requesting Isturisa.

    • Document an inadequate response to at least one of: mifepristone, Signifor or Signifor LAR (pasireotide), Recorlev (levoketoconazole), cabergoline, metyrapone, or Lysodren (mitotane).
    • An exception may be based on intolerance or hypersensitivity to mifepristone, pasireotide, or levoketoconazole, or an FDA-labeled contraindication to all three agents.
    Documentation Required

    Ketoconazole Exception Documentation

    If the patient has not tried ketoconazole tablets with an inadequate response, submit medical records documenting either intolerance or hypersensitivity to ketoconazole tablets or an FDA-labeled contraindication to ketoconazole tablets.

    • Medical records are required for the ketoconazole intolerance, hypersensitivity, or contraindication exception.
    Documentation Required

    Initial Clinical Documentation

    Support the initial request with documentation of the diagnosis or other FDA-labeled indication, the requested agent and route, and the patient's relevant prior treatment history. Include specialist prescriber documentation or evidence of specialist consultation.

    • For Cushing syndrome, document surgical response or candidacy, conventional-agent trial or exception, and ketoconazole tablet trial or exception.
    • For another FDA-labeled indication, document that the requested route and the patient's age are within labeling or provide clinical support for the patient's age.
    Documentation Required

    Renewal Clinical Benefit Documentation

    For renewal, submit evidence that the patient has had clinical benefit with Isturisa and documentation that the prescriber is a specialist in the diagnosis or has consulted with an appropriate specialist.

    • Include the patient's response to therapy and relevant follow-up clinical findings.
    • Confirm prior plan approval through the prior authorization process.
    Documentation Required

    Quantity-Limit Exception Documentation

    When the requested quantity exceeds the program limit, document why the higher dose or quantity is medically supported and why the dose cannot be supplied using a lower quantity of a higher-strength product when applicable.

    • If the indication has no maximum FDA-labeled dose, document support for therapy with the requested higher dose.
    • If a maximum FDA-labeled dose applies, confirm the requested quantity does not exceed that dose and explain why it cannot be achieved with a lower quantity of a higher strength that remains within the program limit.
    Denial Risk

    Indication or Prerequisite Criteria Not Met

    Authorization may be denied when the patient does not have Cushing syndrome meeting the required pathway or another FDA-labeled indication for Isturisa and the requested route, or when required prerequisite therapy or an applicable exception is not documented.

    • Denial-risk conditions include no inadequate response to surgery when surgery was pursued, no documentation that the patient is not a surgical candidate, or failure to meet the conventional-agent and ketoconazole requirements.
    • An FDA-labeled indication does not satisfy criteria unless the requested route and age requirements, or supporting evidence for use at the patient's age, are addressed.
    Denial Risk

    Prohibited Combination or Contraindication

    Deny the request when Isturisa will be used in combination with glucocorticoid replacement therapy for the requested indication or when the patient has an FDA-labeled contraindication to Isturisa.

    • The noncombination requirement applies to both initial and renewal authorization.
    • Document specialist involvement or consultation as required; lack of appropriate specialist support may also prevent approval.
    Denial Risk

    Renewal Requirements Not Met

    Renewal authorization may be denied when prior plan approval is absent, clinical benefit has not been demonstrated, specialist involvement or consultation is not documented, or the renewal requirements regarding glucocorticoid replacement therapy and contraindications are not met.

    • Patients not previously approved through the plan's prior authorization process require initial evaluation review.
    • Insufficient evidence of benefit is a renewal denial condition.
    Denial Risk

    Quantity-Limit Exception Unsupported

    A quantity-limit exception may be denied when the requested dose escalation is unsupported, exceeds the applicable maximum FDA-labeled dose, or lacks documentation showing why the requested quantity cannot be achieved with a lower quantity of a higher-strength product within the program limit.

    • For an indication without a maximum FDA-labeled dose, support for the higher dose is required.
    • The quantity-limit approval period is 12 months.
    The patient tried and had an inadequate response to at least one of the following conventional agents: mifepristone, Signifor/Signifor LAR (pasireotide), Recorlev (levoketoconazole), cabergoline, metyrapone, or Lysodren (mitotane).
  1. The patient has an intolerance or hypersensitivity to mifepristone, pasireotide, or levoketoconazole.
  2. The patient has an FDA-labeled contraindication to mifepristone, pasireotide, and levoketoconazole.
  3. Ketoconazole requirement

    • The patient tried ketoconazole tablets and had an inadequate response.
    • The patient has an intolerance or hypersensitivity to ketoconazole tablets.

      Medical records are required.

    • The patient has an FDA-labeled contraindication to ketoconazole tablets.

      Medical records are required.

  4. Other FDA-labeled indication pathway

    • Age requirement

      • The patient's age is within FDA labeling for the requested indication for the requested agent.
      • There is support for using the requested agent for the patient's age for the requested indication.
  5. General requirements

    • The prescriber is a specialist in the area of the patient's diagnosis, such as an endocrinologist, or the prescriber has consulted with a specialist in that area.
    • The patient will not be using Isturisa in combination with glucocorticoid replacement therapy for the requested indication.
    • The patient does not have any FDA-labeled contraindications to Isturisa.
  6. The patient does not have any FDA-labeled contraindications to Isturisa.